Kv1.3 blockers (Axxam SpA/Juvenile Diabetes Research Foundation/Fast Forward)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameKv1.3 blockers (Axxam SpA/Juvenile Diabetes Research Foundation/Fast Forward)
Drug Alias NameKCNA voltage gated potassium channel 3 inhibitors (Axxam SpA/Juvenile Diabetes Research Foundation/Fast Forward)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel subunit Kv1.3 blockers
TargetsVoltage-gated potassium channel subunit Kv1.3
Therapy Area/IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1Inflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAxxam Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJuvenile Diabetes Research FoundationAxxam SpaFast Forward LLC
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1Inflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A